Dr. Lake D. Morrison, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 530
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 2006-01824 -
Critical Care Medicine (Internal Medicine) Physician
NC license 2206-01824
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
- Novant Health New Hanover Regional Medical Center Wilmington, NC
- Duke Regional Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 530
- Services billed
- 1,276
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 180 | 129 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 80 | 24 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 51 | 42 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 45 | 36 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 44 | 36 |
| Hospital discharge day management, more than 30 minutes | 26 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 18 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Durham, NC | 188 |
| Ofev (nintedanib esylate) | 140 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Durham, NC | 88 |
| Mycophenolate Mofetil Other prescribers in Durham, NC | 82 |
| Pirfenidone | 56 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Durham, NC | 40 |
| Mycophenolic Acid (mycophenolate sodium) | 23 |
| Omeprazole Other prescribers in Durham, NC | 20 |
| Azathioprine Other prescribers in Durham, NC | 18 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Durham, NC | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 4 companies. The companies reported $361,145 in research payments for these studies, mostly to the institutions running them.
- An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase 3, randomized, double-blind, placebo-controlled, parallel grou
GlaxoSmithKline, LLC. - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Idiopathic Pulmonary Fibrosis Prospective Outcome Registry
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or withou…
Boehringer Ingelheim International GmbH - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim International GmbH - PDE4 Phase III trial in IPF patients
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.